| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2720728 | The American Journal of Medicine | 2007 | 8 Pages |
Abstract
Combination therapy with pegylated interferon-alfa and ribavirin for HCV in eligible co-infected patients with stable HIV disease provides substantial life-expectancy benefits and appears to be cost-effective. Overcoming barriers to HCV treatment eligibility among urban co-infected patients remains a critical priority.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Nicole G. MSc, Joshua A. PhD, Julie C. MD, MPH, David P. MD, Jeffrey H. MD, MA, MPH, Kenneth A. MD, MSc, Sue J. MD, MPH,